dipyridamole has been researched along with Breast Neoplasms in 25 studies
Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.
Breast Neoplasms: Tumors or cancer of the human BREAST.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Based upon the hypothesis that dipyridamole would potentiate the cytotoxicity of mitoxantrone and the combination of 5-fluorouracil (5-FU) and leukovorin, we performed a phase I/II trial of the combination of dipyridamole, 5-FU, leukovorin, and mitoxantrone in patients with metastatic breast cancer." | 9.07 | Phase I/II trial of dipyridamole, 5-fluorouracil, leukovorin, and mitoxantrone in metastatic breast cancer. ( Budd, GT; Bukowski, RM; Herzog, P, 1994) |
| "The molecular basis of methotrexate resistance was studied in human MDA-MB-231 breast cancer cells, which are inherently defective in methotrexate uptake and lack expression of the reduced folate carrier (RFC)." | 7.71 | Methylation-dependent silencing of the reduced folate carrier gene in inherently methotrexate-resistant human breast cancer cells. ( Dzhandzhugazyan, KN; Guldberg, P; Kirkin, AF; Worm, J, 2001) |
| "In an attempt to increase the clinical activity of 5-fluorouracil (5-FU) by blocking the thymidine salvage pathway, 15 patients with refractory metastatic breast cancer (MBC) were treated with oral dipyridamole (D): 75 mg p." | 7.67 | 5-Fluorouracil and dipyridamole in metastatic breast cancer: a pilot study. ( Marini, G; Marpicati, P; Montini, E; Palazzi, M; Pipino, G; Simoncini, E; Zaniboni, A, 1989) |
| "Dipyridamole, which has no intrinsic effect on cell growth, transforms a cytostatic response of MDA." | 5.27 | Enhancement of methotrexate cytotoxicity towards the MDA.MB.436 human breast cancer cell line by dipyridamole. The role of methotrexate polyglutamates. ( Clarke, R; Kennedy, DG; Murphy, RF; Van den Berg, HW, 1986) |
| "Based upon the hypothesis that dipyridamole would potentiate the cytotoxicity of mitoxantrone and the combination of 5-fluorouracil (5-FU) and leukovorin, we performed a phase I/II trial of the combination of dipyridamole, 5-FU, leukovorin, and mitoxantrone in patients with metastatic breast cancer." | 5.07 | Phase I/II trial of dipyridamole, 5-fluorouracil, leukovorin, and mitoxantrone in metastatic breast cancer. ( Budd, GT; Bukowski, RM; Herzog, P, 1994) |
| "This study utilised conventional techniques to demonstrate the effects of 4OHT on the expression of ERα and E2F1 and also examined the individual and combined effects of 4OHT with dipyridamole (DIPY) and 3-O-(3,4,5-trimethoxybenzoyl)-(-)-catechin (TMCG) on the oestrogen-negative MDA-MB-231 breast cancer cell line using viability assays, Hoechst staining, MALDI-TOF mass spectroscopy, and confocal microscopy." | 3.80 | Promoting E2F1-mediated apoptosis in oestrogen receptor-α-negative breast cancer cells. ( Collado-González, Mdel M; Fernández-Pérez, MP; Gamkrelidze, M; Hammouda, MB; Montenegro, MF; Rodríguez-López, JN; Tolordava, L, 2014) |
| "Dipyridamole is a widely prescribed drug in ischemic disorders, and it is here investigated for potential clinical use as a new treatment for breast cancer." | 3.79 | Dipyridamole prevents triple-negative breast-cancer progression. ( Bello, AM; De Martino, D; De Vita, G; Di Dato, V; Marino, N; Marshall, JC; Medaglia, C; Navas, L; Romano, A; Scoppettuolo, MN; Spano, D; Steeg, PS; Zollo, M, 2013) |
| "The molecular basis of methotrexate resistance was studied in human MDA-MB-231 breast cancer cells, which are inherently defective in methotrexate uptake and lack expression of the reduced folate carrier (RFC)." | 3.71 | Methylation-dependent silencing of the reduced folate carrier gene in inherently methotrexate-resistant human breast cancer cells. ( Dzhandzhugazyan, KN; Guldberg, P; Kirkin, AF; Worm, J, 2001) |
| "In an attempt to increase the clinical activity of 5-fluorouracil (5-FU) by blocking the thymidine salvage pathway, 15 patients with refractory metastatic breast cancer (MBC) were treated with oral dipyridamole (D): 75 mg p." | 3.67 | 5-Fluorouracil and dipyridamole in metastatic breast cancer: a pilot study. ( Marini, G; Marpicati, P; Montini, E; Palazzi, M; Pipino, G; Simoncini, E; Zaniboni, A, 1989) |
| "Among the 48 human ABC proteins, the breast cancer resistance protein (BCRP/ABCG2) has been described as a pivotal player in cancer resistance." | 2.82 | Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators. ( Delabio, LC; Dutra, JP; Hembecker, M; Kita, DH; Moure, VR; Pereira, GDS; Scheiffer, G; Valdameri, G; Zattoni, IF, 2022) |
| "10]), compared with never use, and there was no evidence of a dose-response relation." | 1.91 | Antiplatelet drugs and breast cancer risk in a large nationwide Danish case-control study. ( Cairat, M; Dossus, L; Fournier, A; Hicks, B; Olesen, M; Pottegård, A, 2023) |
| "More than 85% breast cancers are sporadic and attributable to long-term exposure to environmental carcinogens through a multistep and multiyear disease process." | 1.40 | Dipyridamole intervention of breast cell carcinogenesis. ( Choudhary, S; Sood, S; Wang, HC, 2014) |
| "Formation of lung and extrapulmonary metastases after intravenous administration of MT3 breast cancer cells was significantly reduced when mice were treated with a single intravenous dose of DIP/OPP-L containing 100nmol lipid 6h before tumour cell inoculation." | 1.35 | Inhibition of breast cancer metastasis by dual liposomes to disturb complex formation. ( Fichtner, I; Wenzel, J; Zeisig, R, 2009) |
| "Out of 59 metastatic breast cancer cases analyzed, 22 (37%) were found to overexpress h-prune, evidence that this novel enzymatic activity is involved in promoting cancer metastasis." | 1.32 | Prune cAMP phosphodiesterase binds nm23-H1 and promotes cancer metastasis. ( Aglio, V; André, A; Aravind, L; Arrigoni, G; Carotenuto, P; Cossu, A; D'Angelo, A; Garzia, L; Guardiola, O; Palmieri, G; Zollo, M, 2004) |
| "Among ovarian cancer cell lines tested, the enhancement of the activity of HuIFN by dipyridamole for HAC-2 and SHIN-3 cells was equivalent to or greater than that for 3 chemotherapy agents (adriamycin, vincristine, and a camptothecin derivative)." | 1.28 | Dipyridamole enhances an anti-proliferative effect of interferon in various types of human tumor cells. ( Fukazawa, I; Inaba, N; Isogai, E; Oiwa, Y; Saito-Ebihara, M; Sekiya, S; Sugano, I; Suzuki, N; Takakubo, Y; Yoshida, J, 1992) |
| "Dipyridamole, which has no intrinsic effect on cell growth, transforms a cytostatic response of MDA." | 1.27 | Enhancement of methotrexate cytotoxicity towards the MDA.MB.436 human breast cancer cell line by dipyridamole. The role of methotrexate polyglutamates. ( Clarke, R; Kennedy, DG; Murphy, RF; Van den Berg, HW, 1986) |
| "A case of male breast carcinoma is discussed with reference to the effect of steroids on the hormonal receptors at the malignant cell." | 1.26 | [Clinical demonstrations: 1. Renal tubular acidosis; 2. Breast neoplasm with bone metastases in a man; 3. Thrombotic thrombocytopenic purpura; 4. Precocious eclampsia in a 22 years old primipara]. ( Weber, J, 1977) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (20.00) | 18.7374 |
| 1990's | 5 (20.00) | 18.2507 |
| 2000's | 6 (24.00) | 29.6817 |
| 2010's | 6 (24.00) | 24.3611 |
| 2020's | 3 (12.00) | 2.80 |
| Authors | Studies |
|---|---|
| Virgilio, A | 1 |
| Spano, D | 2 |
| Esposito, V | 1 |
| Di Dato, V | 2 |
| Citarella, G | 1 |
| Marino, N | 2 |
| Maffia, V | 1 |
| De Martino, D | 2 |
| De Antonellis, P | 1 |
| Galeone, A | 1 |
| Zollo, M | 3 |
| Zattoni, IF | 1 |
| Delabio, LC | 1 |
| Dutra, JP | 1 |
| Kita, DH | 1 |
| Scheiffer, G | 1 |
| Hembecker, M | 1 |
| Pereira, GDS | 1 |
| Moure, VR | 1 |
| Valdameri, G | 1 |
| van Leeuwen, JE | 1 |
| Ba-Alawi, W | 1 |
| Branchard, E | 1 |
| Cruickshank, J | 1 |
| Schormann, W | 1 |
| Longo, J | 1 |
| Silvester, J | 1 |
| Gross, PL | 1 |
| Andrews, DW | 1 |
| Cescon, DW | 1 |
| Haibe-Kains, B | 1 |
| Penn, LZ | 1 |
| Gendoo, DMA | 1 |
| Cairat, M | 1 |
| Pottegård, A | 1 |
| Olesen, M | 1 |
| Dossus, L | 1 |
| Fournier, A | 1 |
| Hicks, B | 1 |
| Montenegro, MF | 3 |
| Collado-González, Mdel M | 1 |
| Fernández-Pérez, MP | 1 |
| Hammouda, MB | 1 |
| Tolordava, L | 1 |
| Gamkrelidze, M | 1 |
| Rodríguez-López, JN | 3 |
| González-Guerrero, R | 1 |
| Sánchez-del-Campo, L | 1 |
| Piñero-Madrona, A | 2 |
| Cabezas-Herrera, J | 2 |
| Wenzel, J | 1 |
| Zeisig, R | 1 |
| Fichtner, I | 1 |
| Marshall, JC | 1 |
| Romano, A | 1 |
| Scoppettuolo, MN | 1 |
| Bello, AM | 1 |
| Navas, L | 1 |
| De Vita, G | 1 |
| Medaglia, C | 1 |
| Steeg, PS | 1 |
| Choudhary, S | 1 |
| Sood, S | 1 |
| Wang, HC | 1 |
| Sáez-Ayala, M | 1 |
| Fleming, RM | 1 |
| D'Angelo, A | 1 |
| Garzia, L | 1 |
| André, A | 1 |
| Carotenuto, P | 1 |
| Aglio, V | 1 |
| Guardiola, O | 1 |
| Arrigoni, G | 1 |
| Cossu, A | 1 |
| Palmieri, G | 1 |
| Aravind, L | 1 |
| Budd, GT | 1 |
| Herzog, P | 1 |
| Bukowski, RM | 1 |
| López-Solera, I | 1 |
| Pérez, JM | 1 |
| Monge, MA | 1 |
| Alvarez-Valdés, A | 1 |
| Masaguer, JR | 1 |
| Alonso, C | 1 |
| Navarro-Ranninger, C | 1 |
| Barberi-Heyob, M | 1 |
| Griffon, G | 1 |
| Merlin, JL | 1 |
| Weber, B | 1 |
| Haaz, MC | 1 |
| Fischel, JL | 1 |
| Formento, P | 1 |
| Renée, N | 1 |
| Etienne, MC | 1 |
| Milano, G | 1 |
| Barry, CP | 1 |
| Lind, SE | 1 |
| Worm, J | 1 |
| Kirkin, AF | 1 |
| Dzhandzhugazyan, KN | 1 |
| Guldberg, P | 1 |
| Boyer, CR | 1 |
| Karjian, PL | 1 |
| Wahl, GM | 1 |
| Pegram, M | 1 |
| Neuteboom, ST | 1 |
| Weber, J | 1 |
| Dollinger, MR | 1 |
| Krakoff, IH | 1 |
| Suzuki, N | 1 |
| Oiwa, Y | 1 |
| Sugano, I | 1 |
| Inaba, N | 1 |
| Sekiya, S | 1 |
| Fukazawa, I | 1 |
| Yoshida, J | 1 |
| Takakubo, Y | 1 |
| Isogai, E | 1 |
| Saito-Ebihara, M | 1 |
| Kennedy, DG | 1 |
| Van den Berg, HW | 1 |
| Clarke, R | 1 |
| Murphy, RF | 1 |
| Zaniboni, A | 1 |
| Simoncini, E | 1 |
| Marpicati, P | 1 |
| Montini, E | 1 |
| Palazzi, M | 1 |
| Pipino, G | 1 |
| Marini, G | 1 |
| Chow, S | 1 |
| Roscoe, J | 1 |
| Cattran, DC | 1 |
1 review available for dipyridamole and Breast Neoplasms
| Article | Year |
|---|---|
Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Dr | 2022 |
2 trials available for dipyridamole and Breast Neoplasms
| Article | Year |
|---|---|
Mitochondrial uptake of sestamibi distinguishes between normal, inflammatory breast changes, pre-cancers, and infiltrating breast cancer.
Topics: Adult; Aged; Breast; Breast Neoplasms; Diagnosis, Differential; Dipyridamole; Female; Humans; Male; | 2002 |
Phase I/II trial of dipyridamole, 5-fluorouracil, leukovorin, and mitoxantrone in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Breast Neoplasms; | 1994 |
22 other studies available for dipyridamole and Breast Neoplasms
| Article | Year |
|---|---|
Novel pyrimidopyrimidine derivatives for inhibition of cellular proliferation and motility induced by h-prune in breast cancer.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Breast Neoplasms; Carrier Proteins; Cell Line, Tumor; Cell Move | 2012 |
Computational pharmacogenomic screen identifies drugs that potentiate the anti-breast cancer activity of statins.
Topics: Breast Neoplasms; Cadherins; Cholesterol; Clotrimazole; Dipyridamole; Female; Humans; Hydroxymethylg | 2022 |
Antiplatelet drugs and breast cancer risk in a large nationwide Danish case-control study.
Topics: Aspirin; Breast Neoplasms; Case-Control Studies; Clopidogrel; Denmark; Dipyridamole; Female; Humans; | 2023 |
Promoting E2F1-mediated apoptosis in oestrogen receptor-α-negative breast cancer cells.
Topics: Apoptosis; Breast Neoplasms; Catechin; Cell Line, Tumor; Cell Proliferation; Dipyridamole; Drug Resi | 2014 |
Targeting the epigenetics of the DNA damage response in breast cancer.
Topics: Animals; Apoptosis; BRCA1 Protein; Breast Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; Chrom | 2016 |
Inhibition of breast cancer metastasis by dual liposomes to disturb complex formation.
Topics: Animals; Antineoplastic Agents; Blood Platelets; Breast Neoplasms; Cell Line, Tumor; Dipyridamole; D | 2009 |
Dipyridamole prevents triple-negative breast-cancer progression.
Topics: Animals; Apoptosis; beta Catenin; Blotting, Western; Breast Neoplasms; Cell Adhesion; Cell Cycle; Ce | 2013 |
Dipyridamole intervention of breast cell carcinogenesis.
Topics: Apoptosis; Benzo(a)pyrene; Blotting, Western; Breast; Breast Neoplasms; Carcinogens; Cell Adhesion; | 2014 |
Reactivation of the tumour suppressor RASSF1A in breast cancer by simultaneous targeting of DNA and E2F1 methylation.
Topics: Animals; Apoptosis; Breast Neoplasms; Catechin; Cell Line, Tumor; Chromatin; Chromatin Assembly and | 2012 |
Prune cAMP phosphodiesterase binds nm23-H1 and promotes cancer metastasis.
Topics: Amino Acid Sequence; Bacterial Proteins; Breast Neoplasms; Carrier Proteins; Cell Movement; Dipyrida | 2004 |
Synthesis, crystal structure, and biological activity of a Pt-dipyridamole salt.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Division; Crystallization; Crystallography, X-Ray; Dip | 1994 |
Sequence-dependent growth-inhibitory effects of the in vitro combination of fluorouracil, cisplatin, and dipyridamole.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Division; Cis | 1993 |
Impact of different fluorouracil biochemical modulators on cellular dihydropyrimidine dehydrogenase.
Topics: Allopurinol; Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Ce | 1996 |
Adenosine-mediated killing of cultured epithelial cancer cells.
Topics: Adenine; Adenosine; Adenosine Deaminase Inhibitors; Adenosine Kinase; Apoptosis; Breast Neoplasms; C | 2000 |
Methylation-dependent silencing of the reduced folate carrier gene in inherently methotrexate-resistant human breast cancer cells.
Topics: Acetylation; Antimetabolites, Antineoplastic; Azacitidine; Biological Transport; Breast Neoplasms; C | 2001 |
Nucleoside transport inhibitors, dipyridamole and p-nitrobenzylthioinosine, selectively potentiate the antitumor activity of NB1011.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Bromodeoxyuridine; Carrier | 2002 |
[Clinical demonstrations: 1. Renal tubular acidosis; 2. Breast neoplasm with bone metastases in a man; 3. Thrombotic thrombocytopenic purpura; 4. Precocious eclampsia in a 22 years old primipara].
Topics: Acidosis, Renal Tubular; Acute Kidney Injury; Adrenal Cortex Hormones; Adult; Aged; Bone Neoplasms; | 1977 |
Hemolysis induced by 6-N-hydroxylaminopurine riboside, an adenosine analogue.
Topics: Adenosine; Adult; Bilirubin; Blood Cell Count; Breast Neoplasms; Dipyridamole; Erythrocytes; Female; | 1975 |
Dipyridamole enhances an anti-proliferative effect of interferon in various types of human tumor cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Cell Div | 1992 |
Enhancement of methotrexate cytotoxicity towards the MDA.MB.436 human breast cancer cell line by dipyridamole. The role of methotrexate polyglutamates.
Topics: Arachidonic Acid; Arachidonic Acids; Breast Neoplasms; Cell Count; Cell Line; Dipyridamole; Drug Syn | 1986 |
5-Fluorouracil and dipyridamole in metastatic breast cancer: a pilot study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dipyridamole; Drug To | 1989 |
Plasmapheresis and antiplatelet agents in the treatment of the hemolytic uremic syndrome secondary to mitomycin.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Arginine; Argininosuccinic Ac | 1986 |